Why Invest?
Corporate Strategy
The Company's strategic priorities for 2006 are as follows:
- Focus the Company's financial and operational resources on the development of voclosporin for psoriasis and kidney transplantation.
- Develop and enter into collaborations with third parties. The Company has limited capabilities for the marketing of its products under development. Accordingly, collaborations with third parties who have expertise in commercialization of products may be beneficial to handle this function. Further, such collaborations would provide the Company with financial payments which would assist in the funding of the development of the product and produce royalty income from sales of the product. The Company will also explore in-licensing opportunities to complement its internally developed product pipeline.
- Maintain a strong intellectual property portfolio.
Last updated March 27, 2008